title: Ablation of ventricular arrhythmia in patients with heart failure.
abstract: Ventricular arrhythmias (VAs) in patients with cardiomyopathy and advanced-symptom class heart failure (HF) are associated with significant morbidity and mortality. VAs are typically managed with antiarrhythmic drug therapy and implantable cardiac defibrillators (ICD). Although ICDs are highly effective in reducing sudden cardiac death by termination of VA, they do not prevent arrhythmia recurrences. Recurrent shocks are not only associated with poor quality of life but also progressive HF and increased mortality and morbidity. Radiofrequency catheter ablation has emerged as an important therapeutic option for patients with drug-refractory ventricular tachycardia to reduce or prevent ICD shocks.
authors.affiliation: Division of Cardiovascular Medicine, Department of Cardiac Electrophysiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
authors.forename: William W B
authors.initials: WW
authors.lastname: Chik
authors.affiliation: Division of Cardiovascular Medicine, Department of Cardiac Electrophysiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: francis.marchlinski@uphs.upenn.edu.
authors.forename: Francis E
authors.initials: FE
authors.lastname: Marchlinski
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D017115:Catheter Ablation / Q000379:methods*; D017147:Defibrillators, Implantable / Q000009:adverse effects; D006329:Heart Conduction System / Q000473:pathology; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology; D006339:Heart Rate; D006801:Humans; D018579:Patient Selection; D018570:Risk Assessment; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents
keywords: Ablation; Heart failure; Ventricular arrhythmia; Ventricular assist device